Trial Profile

CPX-351 Plus Enasidenib for Relapsed Acute Myelogenous Leukemia Characterized by the IDH2 Mutation

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cytarabine/daunorubicin (Primary) ; Enasidenib (Primary) ; Cytarabine
Indications Acute myeloid leukaemia
Focus Therapeutic Use

Most Recent Events

26 Sep 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2024.
26 Sep 2023 Status changed from suspended to active, no longer recruiting.
27 Sep 2022 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com